Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis: Margins improve, sales lacklustre - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • May 2, 2002

    Novartis: Margins improve, sales lacklustre

    Novartis India has ended FY02 on an encouraging note. While sales represent a 7% rise, net profit has grown at a faster pace thanks to a rise in operating margins, lower interest cost and positive impact from the closure of the loss making Ciba Vision operations. A sustained rise in margins for all the four quarters of the current year was ensured on the back of better price realisations, control over input costs and re-launch of its key brands.

    (Rs m) FY01 FY02 Change
    Sales 4,384 4,677 6.7%
    Other Income 299 389 30.2%
    Expenditure 3,849 4,028 4.6%
    Operating Profit (EBDIT) 535 650 21.5%
    Operating Profit Margin (%) 12.2% 13.9%  
    Interest 122 32 -73.4%
    Depreciation 100 86 -14.1%
    Profit before Tax 612 921 50.4%
    Tax 194 268 37.9%
    Profit after Tax/(Loss) 418 653 56.1%
    Net profit margin (%) 9.5% 14.0%  
    No. of Shares (eoy) (m) 32.0 32.0  
    Diluted Earnings per share* 13.1 20.4  
    P/E (at current price)   13.5  

    Operating margins for the year would have been higher but for Rs 47 m incurred on VRS and Rs 23 m provided for on account of change in accounting policy for gratuity. Further, other expenditure included Rs 16.6 m provision towards dimunition in the value of investments in US 64. But for these, operating margins would have been 15.7% for FY02, a rise of 350 basis points. Other income however, includes Rs 169 m on account of profit on sale of property at Goregaon.

    % of sales FY01 FY02
    Raw Materials 4.1% 3.3%
    Staff Costs 8.0% 9.8%
    Purchase of finished goods 49.3% 46.3%

    "Pharma sales for the period closed at Rs 2,678 m registering a growth of 7.4% over the previous period. Growth was impacted by lower sales of the companys transplant and oncology range of products.

    In late 2001, the company has carved out the Biochemie segment from the existing pharma business to align the portfolio with that of the parent company. The Biochemie sector primarily focuses on the therapeutic segments of Anti-TB, Anti-DUB (gynaecology) Anti-histamines, Antibiotics, Anti-ulcerants, Anti-diabetes and Cardiovascular. This sector registered sales of Rs 1,220 m which were almost at the same level as prior year sales. On a like to like basis (pharma and Biochemie division consolidated), the company has grown 5%, underperforming industry growth rates due to absence of new products. "

    Consumer Healthcare achieved 11% growth over last year largely driven by its popular OTC brand Calcium Sandoz. An encouraging growth in animal health care business was primarily driven by intensive marketing efforts in cattle and poultry segments and addition of three new licenced-in products in the cattle segment.

    Table Showing Segmentwise operating margins
    FY02 Sales (Rs m) % Growth Margins %*
    Pharma 2,678 7.4% 19.0%
    Biochemie 1,220 - 15.1%
    Consumer Health 416 10.7% 6.4%
    Animal Healthcare Business 363 19.2% 18.1%
    *- Profit before interest and tax      

    At the current market price of Rs 276, the stock trades at 14x its FY02 earnings. The stock is likely to see upside due to attractive forward valuations. We expect the margins of the company to improve further, both due to good performance of its key products and further, restructuring benefits. However, dependence on imports and growth in pharma business, remain key areas of concern.



    Equitymaster requests your view! Post a comment on "Novartis: Margins improve, sales lacklustre". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts